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Redistribution of LRIG Proteins in Psoriasis
Terese Karlsson1, Elisabeth B. Mark2, Roger Henriksson1 and Ha˚kan Hedman1
The human leucine-rich repeats and immunoglobulin-like domains (LRIG) family is composed of three members,
LRIG1, -2, and -3, which are all expressed in human skin. LRIG1 negatively regulates growth factor signaling and is
involved in the regulation of epidermal stem cell quiescence. Ablation of Lrig1 in mice results in psoriasiform
epidermal hyperplasia. Hence, the LRIG proteins may be important for epidermal homeostasis and in psoriasis.
Therefore, we analyzed the LRIG mRNA levels and the cellular and subcellular distribution of LRIG proteins in
normal and psoriatic skin. The mRNA levels of LRIG1, -2, and -3 were not significantly different in psoriatic
epidermis compared to clinically normal epidermis from the same patient. Immunohistochemistry showed that
all three LRIG proteins were expressed in unique and specific patterns both in normal and psoriatic skin.
Intriguingly, in psoriatic epidermis, the LRIG protein expression patterns were altered compared to normal skin.
These results indicate that the LRIG proteins may have a role in epidermal homeostasis and psoriasis.
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INTRODUCTION
Psoriasis is a common, currently incurable, inflammatory
disease affecting 2–3% of the world population (Nickoloff
and Nestle, 2004). In the skin, it is characterized by
epidermal hyperproliferation, abnormal keratinocyte differ-
entiation, and accumulation of T lymphocytes. The immu-
nological component of the disease is clearly important
(Nickoloff and Nestle, 2004); however, dysregulated growth
factor signaling has also been implicated. In mouse models,
ectopic overexpression of the EGFR ligands, transforming
growth factor-a (Vassar and Fuchs, 1991) or amphiregulin
(Cook et al., 1997), or an activated form of the growth factor-
regulated transcription factor Stat3 (Sano et al., 2005) each
result in the development of psoriasis-like skin lesions. In
human epidermis and cultured keratinocytes, EGFR has been
shown to be an essential regulator of multiple cellular
functions, such as cell proliferation and migration (Jost
et al., 2000; Lacouture, 2006). The expression of EGFR in
normal epidermis is mainly confined to the basal and lower
spinous layers (Nanney et al., 1990). However, in psoriatic
skin, EGFR is overexpressed and expression is extended to the
upper spinous layers (Nanney et al., 1984, 1986). Direct
support for a role of EGFR in psoriasis comes from a recent
case report, in which a renal carcinoma patient demonstrated
a total clearance of his psoriasis lesions after 1 month of
treatment with the EGFR/ERBB2 kinase inhibitor lapatinib
(Wierzbicka et al., 2006). Thus, proteins involved in the
regulation of growth factor signaling are evidently important
determinants of psoriasis.
The human leucine-rich repeats and immunoglobulin-like
domains (LRIG) family comprises three integral membrane
proteins, namely LRIG1, -2, and -3 (Suzuki et al., 1996;
Nilsson et al., 2001; Guo et al., 2004; Holmlund et al., 2004).
All three LRIG mRNAs are prominently expressed in human
skin (Nilsson et al., 2001; Guo et al., 2004; Holmlund et al.,
2004), whereas LRIG1 expression is also associated with
epidermal stem cells (Jensen and Watt, 2006). We and others
have shown that LRIG1 negatively regulates growth factor
signaling mediated by EGFR (ERBB) family members (Gur
et al., 2004; Laederich et al., 2004; Goldoni et al., 2007) and
hepatocyte growth factor receptor (MET) (Shattuck et al.,
2007). By this or other mechanisms, LRIG1 regulates
epidermal stem cell quiescence (Jensen and Watt, 2006).
Intriguingly, ablation of the murine Lrig1 gene results in mice
with psoriasiform epidermal hyperplasia (Suzuki et al., 2002).
Furthermore, immunofluorescence results suggest that LRIG1
is downregulated in human psoriatic lesions relative to
normal skin (Suzuki et al., 2002), although no discrete
quantification of LRIG1 RNA or protein levels has been
presented. The subcellular distribution of LRIG proteins is
also potentially important, as their expression is differentially
regulated in different cells and has clinical implications in
certain malignancies (Hedman and Henriksson, 2007). In
astrocytic tumors, for example, perinuclear LRIG protein
localization predicts better patient survival (Guo et al., 2006).
Previously, the subcellular distribution of LRIG1 has not been
analyzed in normal or psoriatic skin nor has LRIG2 or LRIG3
been studied in the context of human skin or psoriasis.
In this study, we used quantitative real-time reverse
transcription (RT)-PCR and immunohistochemistry to analyze
the expression of LRIG mRNA and protein in human psoriatic
lesions and matched clinically normal skin. We show that,
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whereas the LRIG mRNA levels were not changed, the
cellular and subcellular distributions of the LRIG proteins
were altered in human psoriatic lesions compared to normal
epidermis.
RESULTS
LRIG mRNA levels in clinically normal and psoriatic epidermis
Previous studies have suggested that LRIG1 protein is
downregulated in psoriatic skin compared to normal skin.
To address whether the LRIG mRNA levels are altered in
psoriasis, we analyzed the mRNA levels of LRIG1, -2, and -3
in clinically normal epidermis and adjacent psoriatic lesions
from five patients by quantitative real-time RT-PCR (Figure 1).
Although the LRIG1 and LRIG3 levels appeared slightly
reduced in the psoriatic lesions, these apparent changes were
statistically insignificant. There was no statistically significant
difference in the mRNA levels of LRIG1, -2, or -3 between
clinically normal and psoriatic epidermis from the same
patient (Wilcoxon signed ranks test, two-tailed, clinically
normal vs psoriatic: LRIG1, P¼0.225; LRIG2, P¼0.686; and
LRIG3, P¼0.138).
LRIG proteins are redistributed in psoriatic skin compared to
normal skin
The cellular and subcellular distribution of LRIG proteins was
analyzed by immunohistochemistry using polyclonal anti-
bodies specific for LRIG1, -2, and -3, respectively. The
staining patterns of normal skin from healthy donors and
clinically normal skin from psoriasis patients were indis-
tinguishable and, therefore, are interchangeably referred to as
‘‘normal skin,’’ in the following text.
In the majority of normal skin samples, LRIG1 was mainly
expressed in the lower spinous layers (Figure 2a). The staining
was mainly cytoplasmic, but some nuclei in the spinous and
granular layers were also positive. LRIG1 was often present at
the cell borders in the lower spinous layers. In the basal cell
layer, LRIG1 was expressed in the nuclei by scattered cells. In
a subgroup of normal skin samples, LRIG1 was mainly
expressed in the nuclei throughout the epidermis (Figure 2c).
In psoriatic epidermis, LRIG1 was cytoplasmically expressed in
the spinous layers (Figure 2b). Notably, in psoriasis, LRIG1 was
mostly absent from the cell surfaces in the spinous layers as
evident by lack of LRIG1 immunoreactivity at the cell borders.
Also, nuclear LRIG1 expression was frequently less prominent
in psoriatic lesions compared to levels in normal skin.
LRIG2, in normal skin, was predominantly expressed in the
basal and lower spinous layers (Figure 2d). The immuno-
reactivity was mainly cytoplasmic, but LRIG2 was also often
detected at the cell borders in the basal and lower spinous
layers. Some nuclei throughout the epidermis also showed
LRIG2 immunoreactivity. In psoriasis, LRIG2 expression was
notably extended from the basal and lower spinous layers into
the upper spinous layers (Figure 2e). Similar to LRIG1, LRIG2
was mostly absent from the cell borders in psoriatic lesions.
LRIG3, in normal skin was similar to LRIG2, expressed
cytoplasmically in the basal and lower spinous layers (Figure
2f). However, compared to LRIG2, the nuclear staining was
much more profound and it was seen throughout the spinous
layers. Also, the cell surface staining of LRIG3 was more
distinct than that of LRIG1 and LRIG2. In the basal cell layer,
nuclear LRIG3 expression was often stronger at the bottom of
the rete ridges, whereas the cytoplasmic staining was stronger
at the top. Nuclei in the granular layer also showed LRIG3
immunoreactivity. In addition, many dermal cells expressed
LRIG3. In psoriasis, LRIG3 expression was extended from the
lower spinous layers to the upper spinous layers (Figure 2g). In
contrast to LRIG1 and LRIG2, LRIG3 was frequently localized
at the cell borders in both normal and psoriatic skin.
DISCUSSION
This is to our knowledge the first thorough evaluation of
LRIG1, -2, and -3 in normal and psoriatic skin. The results
showed that (i) LRIG proteins were expressed in unique and
distinct patterns in normal and psoriatic skin, (ii) the expression
patterns of LRIG proteins were altered in psoriatic lesions
compared to normal skin, and (iii) the levels of LRIG mRNA
were not significantly changed in psoriatic lesions compared
to clinically normal epidermis obtained from the same patient.
The present investigation was undertaken because pre-
vious studies had suggested that LRIG1 is important for
epidermal homeostasis (Suzuki et al., 2002; Jensen and Watt,
2006). We found that LRIG1 protein in normal skin was
expressed by scattered basal cells, possibly representing
epidermal stem cells, as previously reported (Jensen and
Watt, 2006). In addition, we found expression of LRIG1 in the
spinous and granular layers. Here, it should be noted that the
antibody used in this study recognized an intracellular
epitope of LRIG1, whereas the antibody used by others
(Suzuki et al., 2002; Jensen and Watt, 2006) recognizes an
extracellular or luminal epitope of LRIG1. Recent results from
our group have shown that LRIG1 can be proteolytically
cleaved (Nilsson et al., 2003), and the extracellular domain of
LRIG1 can be released (Yi et al., our unpublished observa-
tions). It is, thus, possible that the different domains of LRIG1
upon protein cleavage localize to different epidermal regions
and subcellular compartments. Therefore, it would not be
surprising if different LRIG1 antibodies reveal different
expression patterns. Whether this actually is the case and
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Figure 1. LRIG mRNA levels in psoriatic lesions and clinically normal
epidermis from the same patient. Quantitative real-time RT-PCR was used to
analyze the mRNA expression of LRIG1, -2, -3, and 18S rRNA in clinically
normal and psoriatic epidermis from the same patient (n¼5). Results are
shown as LRIG/18S rRNA ratios in arbitrary units with error bars indicating SD.
Black bars, clinically normal epidermis; white bars, psoriatic epidermal lesions.
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whether the different proteolytic LRIG1 fragments have
biological activities will be important subjects for future studies.
Our analysis of RNA from psoriatic lesions and clinically
normal epidermis from five patients with psoriasis and tissue
sections from 25 psoriatic patients and 15 normal controls did
not reveal a downregulation of either of the LRIG transcripts
or proteins in psoriatic lesions. This contrasts with a previous
study (Suzuki et al., 2002), which suggested that LRIG1
protein was downregulated in psoriasis. Again, it should be
noted that in this previous study, an antibody against an
extracellular or luminal epitope of LRIG1 was used, whereas
the antibody used by us was against an intracellular epitope.
It is, thus, possible that increased LRIG1 ectodomain
shedding in psoriasis could result in the disappearance
(‘‘downregulation’’) of the extracellular epitope, whereas
the intracellular epitope is retained cytoplasmically and
therefore would not appear downregulated. Importantly, in
our analysis, we found that the cellular and subcellular
distribution of LRIG proteins was altered in psoriatic
epidermis compared to normal skin. For example, in contrast
to the situation in normal skin, in psoriatic lesions, LRIG1 and
LRIG2 seemed to be absent from the cell surfaces and LRIG1
appeared to be excluded from the cell nuclei. To address the
questions of the mechanisms and consequences of this
redistribution of LRIG proteins in psoriatic lesions, further
investigations are prompted. It will be most important to
address the question of whether LRIG protein redistribution is
part of the etiology of psoriasis or an epiphenomenon. It is, for
example, plausible that the change of LRIG protein localiza-
tion in psoriasis impinges on the expression and activity of
EGFR in psoriasis, thereby affecting the disease process.
Not much is known about the functions of LRIG2 and
LRIG3. Nevertheless, both LRIG2 and LRIG3 showed distinct
and unique expression patterns in normal skin, which was
altered in psoriatic lesions. Understanding the exact role of the
LRIG proteins in normal and pathologic epidermis requires a
better understanding of their molecular functions. However,
the results herein presented are consistent with earlier
assertions for an important role for LRIG proteins in epidermal
homeostasis, and indicate their involvement in psoriasis.
MATERIALS AND METHODS
RNA and quantitative real-time RT-PCR
Patient selection and the isolation of RNA has previously been
described (Mark et al., 2006). Patients gave their informed consent
and this part of the study was approved by the Ethics Committee at
Figure 2. Distribution of LRIG proteins in normal skin and psoriatic lesions. Skin tissue sections were labeled with specific LRIG antibodies (brown) and
hematoxylin nuclear counterstain (blue). Normal skin (a, c, d, and f) and psoriatic lesions (b, e, and g) were labeled for LRIG1 (a–c), LRIG2 (d and e), or LRIG3
(f and g). Square insets are magnified and shown to the right of the respective figure. Bar¼ 100mm.
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the Medical Faculty, Go¨teborg University, and performed in
accordance with the Declaration of Helsinki Principles. Patients
with mild or moderate psoriasis with no ongoing treatment for their
psoriasis within 3 weeks were selected at the outpatient clinic of
the Department of Dermatology, Sahlgrenska University Hospital,
Go¨teborg. The age distribution of this patient cohort was as
following: mean age, 55.4 years; median age, 63 years; range,
39–77 years. From five patients, a 4mm punch biopsy was taken on
clinically active psoriatic-involved skin and uninvolved skin in the
same area. The biopsies were taken on untanned skin, in the gluteal
region, under local anesthesia (1% lidocaine without adrenaline).
The dermis was macroscopically excised. The samples were
immediately frozen in liquid nitrogen. Total RNA from the tissue
was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
The homogenization was performed both with a Polytron PT3100
and a syringe. The RNA samples were treated with DNaseI before
analysis. The RNA expression of 18S rRNA, LRIG1, -2, and -3 was
analyzed by quantitative real-time RT-PCR as described earlier (Guo
et al., 2004). All samples were analyzed in triplicate and the SD
were in all cases o30% of the mean.
Immunohistochemical staining
Punch biopsies from 25 additional patients diagnosed with psoriasis
and 15 healthy age- and sex-matched volunteers were taken and
treated as described elsewhere (Gu et al., 2006). Patients gave their
informed consent and this part of the study was approved by the
Ethics Committee at Umea˚ University and performed in accordance
with the Declaration of Helsinki Principles. The age distribution of
this patient cohort was as following: mean age, 46.1 years; median
age, 48 years; range, 23–73 years. The biopsies were formalin-fixed,
paraffin-embedded, sectioned, and stained using a Ventana staining
machine as previously described (Gu et al., 2006), except that
antigen retrieval was performed in 10mM citrate buffer, pH 7.3. The
polyclonal rabbit anti-LRIG antibodies have previously been
described (Nilsson et al., 2003; Holmlund et al., 2004; Guo et al.,
2006) and were used at the following concentrations: LRIG1,
3mgml1; LRIG2, 5.8 mgml1; and LRIG3, 11mgml1.
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